Trinity Biotech Announces Successful Clinical Results for Its Enhanced EpiCapture™ Prostate Cancer Test

Core Insights - Trinity Biotech has announced the successful results of a clinical study for an enhanced version of its EpiCapture™ prostate cancer test, which utilizes machine learning for improved risk prediction of aggressive prostate cancer [1][6]. Group 1: Product Development and Clinical Validation - The next-generation EpiCapture™ test incorporates machine learning tools that consider additional patient features, including ethnicity, alongside DNA biomarkers, leading to more accurate risk prediction scores [2]. - The upgraded test was evaluated in a clinical study involving approximately 750 patient samples, providing a more ethnically diverse cohort than previous studies [5]. - The new version of the EpiCapture™ test achieved a clinical accuracy (Area Under the Curve, AUC) of 85%, indicating strong performance in oncology diagnostics [6]. Group 2: Market Context and Need - Prostate cancer is the most common non-skin cancer among men in the U.S., with about 1 in 8 men diagnosed during their lifetime, and national expenditures for prostate cancer care exceeding $20 billion annually [4]. - The EpiCapture test offers a less invasive and more accessible alternative to traditional diagnostic methods, addressing barriers to early detection such as the high costs and risks associated with MRI scans and needle biopsies [3]. Group 3: Commercialization Strategy - Trinity Biotech plans to commercialize the EpiCapture test as a proprietary Laboratory Developed Test (LDT) through its New York State Department of Health certified diagnostics reference laboratory, facilitating rapid rollout across the U.S. [8]. - This marks Trinity Biotech's first entry into the precision oncology diagnostics market, reflecting the company's strategic evolution towards precision medicine applications [9]. Group 4: Expert Commentary - John Gillard, CEO of Trinity Biotech, emphasized that the enhanced EpiCapture test represents significant progress in prostate cancer risk prediction and the company's innovation agenda [10]. - Dr. Antoinette Perry from University College Dublin highlighted the study's strong performance and the test's unique incorporation of ethnicity as a variable in its predictive algorithm, addressing the variations in prostate cancer incidence and outcomes across different populations [10].